Brocklesby, K.L.Waby, Jennifer S.Cawthorne, C.Smith, G.2019-10-102019-10-102019-10-102019-10-102017-04-12Brocklesby KL, Waby JS, Cawthorne C et al (2017) An alternative synthesis of Vandetanib (CaprelsaTM) via a microwave accelerated Dimroth rearrangement. Tetrahedron Letters. 58(15): 1467-1469.RMSID:212515643http://hdl.handle.net/10454/17298YesVandetanib is an orally available tyrosine kinase inhibitor used in the treatment of cancer. The current synthesis proceeds via an unstable 4-chloroquinazoline, using harsh reagents, in addition to requiring sequential protection and deprotection steps. In the present work, use of the Dimroth rearrangement in the key quinazoline forming step enabled the synthesis of Vandetanib in nine steps (compared to the previously reported 12–14).en©2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).VandetanibQuinazolineDimroth rearrangementTyrosine kinase inhibitorAn alternative synthesis of Vandetanib (CaprelsaTM) via a microwave accelerated Dimroth rearrangementArticlehttps://doi.org/10.1016/j.tetlet.2017.02.082CC-BY2019-10-10